Search research articles
Contact Us
Filters
Showing results (141-150 of 176) with videos related to
Page
of 18
Sort By:
Cancer Medicine
|
March 19, 2024
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors
Dejan Juric, Minal Barve, Ulka Vaishampayan, et al.
Clinical Genitourinary Cancer
|
April 5, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium
Martin Zarba, David Maj, Razane El Hajj Chehade, et al.
The Oncologist
|
April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer
Aristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Biorxiv : the Preprint Server for Biology
|
April 8, 2024
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer
Jie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2019
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A McGregor, Rana R McKay, David A Braun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Pedro Barata, Catherine Tangen, Melissa Plets, et al.
European Urology
|
November 5, 2013
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
Fabio A B Schutz, Wanling Xie, Frede Donskov, et al.
British Journal of Clinical Pharmacology
|
July 5, 2019
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
Naoko Takebe, Jan H Beumer, Shivaani Kummar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
Toni K Choueiri, Robert W Ross, Susanna Jacobus, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 176) with videos related to
Sort By:
Page
of 18
Cancer Medicine
|
March 19, 2024
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors
Dejan Juric, Minal Barve, Ulka Vaishampayan, et al.
Clinical Genitourinary Cancer
|
April 5, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium
Martin Zarba, David Maj, Razane El Hajj Chehade, et al.
The Oncologist
|
April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer
Aristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
Biorxiv : the Preprint Server for Biology
|
April 8, 2024
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer
Jie Luo, Zhixiang Chen, Yuanyuan Qiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 14, 2019
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A McGregor, Rana R McKay, David A Braun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Pedro Barata, Catherine Tangen, Melissa Plets, et al.
European Urology
|
November 5, 2013
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
Fabio A B Schutz, Wanling Xie, Frede Donskov, et al.
British Journal of Clinical Pharmacology
|
July 5, 2019
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
Naoko Takebe, Jan H Beumer, Shivaani Kummar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2011
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
Toni K Choueiri, Robert W Ross, Susanna Jacobus, et al.
Page
of 18